ETF建议更新新冠肺炎疫苗，以针对新的JN.1变种-动脉网

ETF recommends updating COVID-19 vaccines to target new JN.1 variant

EMA 等信源发布 2024-04-30 18:07



可切换为仅中文







EMA’s Emergency Task Force (ETF) has recommended updating COVID-19 vaccines to target the new SARS-CoV-2 variant JN.1 for the 2024/2025 vaccination campaign.JN.1 differs from the XBB family targeted by previous updated vaccines and has now surpassed the XBB variants to become the most widely circulating variant worldwide.In making its recommendation, the ETF consulted the World Health Organization (WHO), international partners and marketing authorisation holders for COVID-19 vaccines.

EMA的紧急工作组（ETF）建议更新COVID-19疫苗，以针对2024/2025年疫苗接种活动中新的SARS-CoV-2变异JN.1。1不同于以前更新的疫苗所针对的XBB家族，现在已经超过了XBB变体，成为全球传播最广泛的变体。在提出建议时，ETF咨询了世界卫生组织（WHO）、国际合作伙伴和新型冠状病毒疫苗上市许可持有人。

The ETF also considered a wide range of data, including data on the evolution of the virus and data from animal studies on the effects of candidate vaccines targeting JN.1.The evidence indicates that targeting JN.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.Marketing authorisation holders should now contact EMA to discuss updates to the marketing authorisations of their vaccines.

ETF还考虑了广泛的数据，包括病毒进化的数据以及动物研究中针对JN.1候选疫苗效果的数据。证据表明，随着SARS-CoV-2的不断发展，针对JN.1将有助于维持疫苗的有效性。上市许可持有人现在应联系EMA，讨论其疫苗上市许可的更新。

All marketing authorisation holders are expected to update the composition of their authorised vaccines in accordance with this recommendation.Companies currently developing new COVID-19 vaccines not targeting JN.1 are also encouraged to contact EMA to discuss strategies for changing the composition of their vaccines.National authorities in the EU will ultimately make decisions about vaccination campaigns for 2024 and 2025, taking into account the situation in their country..

所有上市许可持有人均应根据本建议更新其授权疫苗的组成。目前正在开发不针对JN.1的新型COVID-19疫苗的公司也被鼓励与EMA联系，讨论改变疫苗组成的策略。欧盟国家当局将考虑到本国的情况，最终决定2024年和2025年的疫苗接种运动。。